Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM)’s share price traded down 11.7% during mid-day trading on Monday . The company traded as low as $0.47 and last traded at $0.48. 1,319,186 shares changed hands during trading, an increase of 72% from the average session volume of 766,801 shares. The stock had previously closed at $0.54.

A number of equities analysts have recently issued reports on the company. Oppenheimer set a $5.00 price target on Actinium Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, February 26th. Zacks Investment Research raised Actinium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price target on the stock in a research report on Monday, April 1st. Finally, Maxim Group set a $3.00 price target on Actinium Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, February 5th. Five investment analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average target price of $3.50.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last released its earnings results on Tuesday, March 19th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06).

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ATNM. PNC Financial Services Group Inc. acquired a new position in shares of Actinium Pharmaceuticals in the 3rd quarter valued at $617,000. Vanguard Group Inc increased its position in shares of Actinium Pharmaceuticals by 6.4% in the 3rd quarter. Vanguard Group Inc now owns 2,575,754 shares of the biotechnology company’s stock valued at $1,909,000 after acquiring an additional 154,403 shares during the period. Vanguard Group Inc. increased its position in shares of Actinium Pharmaceuticals by 6.4% in the 3rd quarter. Vanguard Group Inc. now owns 2,575,754 shares of the biotechnology company’s stock valued at $1,909,000 after acquiring an additional 154,403 shares during the period. Finally, Virtu Financial LLC increased its position in shares of Actinium Pharmaceuticals by 103.1% in the 3rd quarter. Virtu Financial LLC now owns 195,623 shares of the biotechnology company’s stock valued at $146,000 after acquiring an additional 99,318 shares during the period.

WARNING: This story was first posted by Daily Political and is the property of of Daily Political. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://www.dailypolitical.com/2019/04/15/actinium-pharmaceuticals-atnm-stock-price-down-11-7.html.

Actinium Pharmaceuticals Company Profile (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.

Further Reading: How liquidity affects the bid-ask spread

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.